Outlook Therapeutics (OTLK) Change in Account Payables (2015 - 2026)
Outlook Therapeutics (OTLK) reported Change in Account Payables of $5.7 million for Q1 2026, up 223.25% year-over-year from $1.8 million in Q1 2025, and up 298.56% quarter-over-quarter from -$2.9 million in Q4 2025.
Outlook Therapeutics (OTLK) Change in Account Payables (2015 - 2026) Analysis & Trends
Outlook Therapeutics (OTLK) has 12 years of Change in Account Payables data on file, last reported at $5.7 million in Q1 2026.
- Change in Account Payables for Q1 2026 came in at $5.7 million, up 223.25% year-over-year; the trailing twelve-month figure through Mar 2026 was $4.9 million (up 28.53% YoY), and the FY2025 annual result was $1.7 million, up 19.5% from the prior year.
- Change in Account Payables climbed to $5.7 million in Q1 2026 per OTLK's latest filing, from -$2.9 million in the prior quarter.
- Over five years, Change in Account Payables peaked at $5.7 million in Q1 2026 and troughed at -$4.6 million in Q1 2025.
- A 5-year average of $594220.5 and a median of $1.0 million in 2022 frame the typical range for Change in Account Payables.
- The sharpest annual moves came in 2022 and 2025: Change in Account Payables surged 357.48% in 2022, then tumbled 1833.96% in 2025.
- A 5-year view of Change in Account Payables shows it stood at $678394.0 in 2022, then plunged by 556.11% to -$3.1 million in 2023, then surged by 236.51% to $4.2 million in 2024, then slumped by 168.03% to -$2.9 million in 2025, then jumped by 298.56% to $5.7 million in 2026.
- Business Quant data shows OTLK's Change in Account Payables at $5.7 million in Q1 2026, -$2.9 million in Q4 2025, and $30255.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | -3.26 Mn |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 35.60 Mn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | -9.42 Mn |
| 10 | Outlook Therapeutics | 51.56 Mn | 43.81 Mn | -21,888.00 | 5.71 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.71 Mn |
| Mar 31, 2026 | 5.71 Mn |
| Dec 31, 2025 | -2.87 Mn |
| Dec 31, 2025 | -2.87 Mn |
| Sep 30, 2025 | 30,255.00 |
| Sep 30, 2025 | 30,255.00 |
| Jun 30, 2025 | 2.04 Mn |
| Jun 30, 2025 | 2.04 Mn |
| Mar 31, 2025 | -4.63 Mn |
| Mar 31, 2025 | -4.63 Mn |
| Dec 31, 2024 | 4.22 Mn |
| Dec 31, 2024 | 4.22 Mn |
| Sep 30, 2024 | 2.53 Mn |
| Sep 30, 2024 | 2.53 Mn |
| Jun 30, 2024 | 1.69 Mn |
| Jun 30, 2024 | 1.69 Mn |
| Mar 31, 2024 | 267,002.00 |
| Mar 31, 2024 | 267,002.00 |
| Dec 31, 2023 | -3.09 Mn |
| Dec 31, 2023 | -3.09 Mn |